<DOC>
	<DOC>NCT01320085</DOC>
	<brief_summary>The study will assess the safety and efficacy of single-agent MEK162 in adult patients with locally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring BRAFV600E or NRAS mutations.</brief_summary>
	<brief_title>A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Locally advanced or metastatic cutaneous melanoma AJCC Stage IIIB to IV, not potentially curable with surgery BRAF or NRAS mutation in tumor tissue All patients enrolled should provide sufficient fresh or archival tumor sample at baseline to enable confirmation of BRAF or NRAS mutations and the additional analyses described in the protocol Evidence of measurable tumor disease as per RECIST WHO performance status of 02 Adequate organ function and laboratory parameters History or evidence of central serous retinopathy (CSR), retinal vein occlusion (RVO) or any eye condition that would be considered a risk factor for CSR or RVO Patients with unstable CNS metastasis Prior treatment with a MEK inhibitor Impaired cardiovascular function HIV, active Hepatitis B, and/or active Hepatitis C infection Pregnant or nursing (lactating) women Women of childbearing potential UNLESS they comply with protocol contraceptive requirements Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Metastatic melanoma,</keyword>
	<keyword>BRAF-mutant,</keyword>
	<keyword>NRAS-mutant</keyword>
</DOC>